CATX Perspective Therapeutics, Inc.
Price Chart
Executive Summary
Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, [²¹²Pb]PSV359) at ASCO 2026. The updates confirm previously disclosed response rates and safety profiles — no transformative new efficacy signal was introduced. The disclosure is procedural (conference presentation), not a material event that changes the investment thesis.
Actionable Insight
The press release confirms continued dose-escalation and tolerability across all programs but provides no new decisive efficacy readout. ASCO posters in late May may provide incremental detail, but the material catalyst remains the next formal data update expected in late 2026. With the stock down -12% T+20 on average after recent CATX reports, market already discounts clinical risk. No immediate trading catalyst from this filing alone.
Key Facts
- Data for [212Pb]VMT-α-NET (n=25 efficacy, n=68 safety) consistent with prior AACR disclosures; deepening responses observed with ~6 weeks additional follow-up
- [212Pb]VMT01 melanoma cohort: 2 confirmed responses out of 7 (29%) in 3.0 mCi monotherapy; 6/7 (86%) with stable disease or partial response
- [212Pb]PSV359 advanced to Cohort 3 (6.0 mCi) with no DLTs; Grade 1-2 TEAEs only
- ASCO presentations scheduled May 30-31, 2026; further data across all programs expected in late 2026
- [212Pb]VMT01 has FDA Fast Track Designation (granted Sep 2024)
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech with no current product sales or guidance
Risk Factors
- Phase 1/2a data remain early-stage; no registrational trial initiation yet announced
- Response rates in VMT01 (29% in monotherapy) are modest; combination with nivolumab cohort (n=6) data immature
- VMT-α-NET competition from established approved therapies (Lutathera, F-177Lu edotreotide) with proven OS data
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299819 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.34%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.17%) |
|
Jun 3, 2026
11d ago
|
Press Release
| $3.56 $3.25 | ▼ −8.71% | ▼ −9.11% | $2.95 (−17.13%) |
|
Jun 1, 2026
13d ago
|
8-K
| $3.66 $3.60 | ▼ −1.64% | ▼ −1.78% | $2.95 (−19.40%) |
|
May 21, 2026
24d ago
|
Press Release
| $3.98 $4.16 | ▲ +4.52% | ▲ +3.94% | $2.95 (−25.88%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.76 $3.63 | ▼ −3.46% | ▼ −2.81% | $2.95 (−21.54%) |
|
May 11, 2026
4w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▼ −0.54% | $2.95 (−21.75%) |
|
May 4, 2026
5w ago
|
8-K
| $3.65 $3.82 | ▲ +4.66% | ▲ +3.27% | $2.95 (−19.18%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $4.51 $4.27 | ▼ −5.32% | ▼ −5.49% | $2.95 (−34.59%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.55 $4.64 | ▲ +1.98% | ▲ +2.63% | $2.95 (−35.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access